Meikang Bio: The company’s new crown nucleic acid detection kit and antigen detection kit (medical version) have obtained CE certification in 2021_ Oriental Fortune Network

Every time the AI ​​​​express, some investors ask questions on the investor interaction platform: Wuhan todayMatilda BioThe new crown test kit was approved by the State Food and Drug Administration for marketing. What is the reason for the delay in submitting the application for your company’s new crown testing products? Or is there no product at all? Want the secretary to answer truthfully? The company’s stock price has hit a two-year low. Are there any measures for market value management?

　　Meikang Bio(300439.SZ) said on the investor interactive platform on April 14 that the company’s new coronavirus COVID-19 nucleic acid detection kit and new coronavirus 2019-nCoV antigen detection kit (medical version) have obtained CE certification in 2021.domesticmedical instrumentsProduct registration needs to meet the relevant laws and regulations of the State Food and Drug Administration. The company is actively promoting the domestic registration of three new crown detection products: nucleic acid, antibody and antigen.The company strives to take practical actions to run the company well, makeperformance, and give investors a real return. The capital market is affected by many factors, please pay attention to investment risks.

(Reporter Hu Ling)

(Article source: Daily Economic News)

Article source: Daily Economic News

Responsible editor: 6

Original title: Meikang Bio: The company’s new crown nucleic acid detection kit and antigen detection kit (medical version) have obtained CE certification in 2021